Website value calculator & SEO Checker => immuno-oncologynews.com
SEO report with information and free domain appraisal for immuno-oncologynews.com. It is a domain hosted in . Its server is hosted on IP 172.67.135.121. The domain is ranked at the number 1266161 as a world ranking of web pages. According to estimated data we have access to potential gains of this site are 42 dollars per month. In annual terms, the domain immuno-oncologynews.com could be earning more than 509 dollars. If someone wanted to buy the domain a good selling price would be 5087 dollars.
These data are estimated and can not be taken as 100 % real. Only give an estimate of profits depending on the subject and the traffic generated by immuno-oncologynews.com . The estimated number of unique visitors accessing immuno-oncologynews.com is 370. Thus the total number of people who visit this page per month would be 11111 people.
Domain Authority
SEO Score
☰ Report Resume
- SEO score
- Speed
- Page Load Time
- Current Ip of the domain: 172.67.135.121
- Charset of page: UTF-8
- Total Keywords: 2648
- Total Links: Anchor textTypeLinkfollowhttps://immuno-oncologynews.com/Skip to contentfollow#contentHomefollowhttps://immuno-oncologynews.comCategoriesfollowhttps://immuno-oncologynews.com/categories/Immune Checkpoint Inhibitorsfollowhttps://immuno-oncologynews.com/immune-checkpoint-inhibitors/T cellsfollowhttps://immuno-oncologynews.com/tag/t-cells/PD-1followhttps://immuno-oncologynews.com/tag/pd-1/Melanomafollowhttps://immuno-oncologynews.com/tag/melanoma/Breast Cancerfollowhttps://immuno-oncologynews.com/tag/breast-cancer/Cancer Vaccinesfollowhttps://immuno-oncologynews.com/tag/cancer-vaccine/FDAfollowhttps://immuno-oncologynews.com/tag/fda/Immuno-Oncologyfollowhttps://immuno-oncologynews.com/immuno-oncology/TherapiesfollowApproved Drugsfollow#Bavencio (Avelumab)followhttps://immuno-oncologynews.com/bavencio/Imfinzi (Durvalumab)followhttps://immuno-oncologynews.com/imfinzi-durvalumab/Keytruda (Pembrolizumab)followhttps://immuno-oncologynews.com/keytruda-pembrolizumab/Kymriah (Tisagenlecleucel)followhttps://immuno-oncologynews.com/kymriah-tisagenlecleucel/Opdivo (Nivolumab)followhttps://immuno-oncologynews.com/opdivo-nivolumab/Tecentriq (atezolizumab)followhttps://immuno-oncologynews.com/tecentriq/Unituxin (Dinutuximab)followhttps://immuno-oncologynews.com/unituxin-dinutuximab/Yervoy (Ipilimumab)followhttps://immuno-oncologynews.com/yervoy-ipilimumab/Yescarta (Axicabtagene Ciloleucel) – Formerly KTE-C19followhttps://immuno-oncologynews.com/kte-c19-axicabtagene-ciloleucel/Experimental Therapiesfollow#afollowABBV-181followhttps://immuno-oncologynews.com/abbv-181/ABBV-428followhttps://immuno-oncologynews.com/abbv-428/ABP798followhttps://immuno-oncologynews.com/abp-798/Actimmunefollowhttps://immuno-oncologynews.com/actimmune/Adagloxad Simoleninfollowhttps://immuno-oncologynews.com/adagloxad-simolenin/ADU-741 (JNJ-64041809 )followhttps://immuno-oncologynews.com/adu-741-jnj-64041809/ADXS-HER2followhttps://immuno-oncologynews.com/adxs-her2/ADXS-PSAfollowhttps://immuno-oncologynews.com/adxs-psa/AE37followhttps://immuno-oncologynews.com/ae37/AFM11followhttps://immuno-oncologynews.com/afm11/AFM13followhttps://immuno-oncologynews.com/afm13/Zalifrelimab (AGEN1884)followhttps://immuno-oncologynews.com/agen-1884/Balstilimab (AGEN2034)followhttps://immuno-oncologynews.com/agen2034/ALKS 4230followhttps://immuno-oncologynews.com/alks-4230/AlloStimfollowhttps://immuno-oncologynews.com/allostim/AM0010 (Pegilodecakin)followhttps://immuno-oncologynews.com/am0010/AMG 211 (MEDI-565)followhttps://immuno-oncologynews.com/amg-211-medi-565/AMG 330followhttps://immuno-oncologynews.com/amg-330/AMG 420followhttps://immuno-oncologynews.com/amg-420/APVO414 (MOR209/ES414)followhttps://immuno-oncologynews.com/apvo414/AST-VAC1followhttps://immuno-oncologynews.com/ast-vac1/ATA520followhttps://immuno-oncologynews.com/ata520/AutoSynVaxfollowhttps://immuno-oncologynews.com/autosynvax/b-cfollowIdecaptagene Cicleucel (Ide-Cel; Previously bb2121)followhttps://immuno-oncologynews.com/bb2121/BGB324 (bemcentinib)followhttps://immuno-oncologynews.com/bemcentinib-bgb324/Tislelizumab (Previously BGB-A317)followhttps://immuno-oncologynews.com/tislelizumab/Blincyto (blinatumomab)followhttps://immuno-oncologynews.com/blincyto-blinatumomab/Biropepimut-S (GL-0817)followhttps://immuno-oncologynews.com/biropepimut-s-gl-0817/BMS 986178followhttps://immuno-oncologynews.com/bms-986178/BPX-501followhttps://immuno-oncologynews.com/bpx-501/BPX-601followhttps://immuno-oncologynews.com/bpx-601/BriaVaxfollowhttps://immuno-oncologynews.com/briavax/Canakinumabfollowhttps://immuno-oncologynews.com/canakinumab/Cavatak (Coxsackievirus – CVA21)followhttps://immuno-oncologynews.com/cavatak-coxsackievirus-cva21/CBT-501 (genolimzumab)followhttps://immuno-oncologynews.com/cbt-501-genolimzumab/CBT-502followhttps://immuno-oncologynews.com/cbt-502-anti-pd-l1/Cergutuzumab Amunaleukinfollowhttps://immuno-oncologynews.com/cergutuzumab-amunaleukin/CMP-001followhttps://immuno-oncologynews.com/immuno-oncology-therapy-cmp-001-boosts-immune-response-to-skin-cancer/CMD-003 (Baltaleucel-T)followhttps://immuno-oncologynews.com/cmd-003-baltaleucel-t/CRISPR/Cas9 and Cancerfollowhttps://immuno-oncologynews.com/crisprcas9-and-cancer/CRS-207followhttps://immuno-oncologynews.com/crs-207/CS1001followhttps://immuno-oncologynews.com/cs1001/CX-072followhttps://immuno-oncologynews.com/cx-072/D-FfollowDCVaxfollowhttps://immuno-oncologynews.com/dcvax/DI-Leu16-IL2followhttps://immuno-oncologynews.com/di-leu16-il2/DNX-2401followhttps://immuno-oncologynews.com/dnx-2401/DPX-E7followhttps://immuno-oncologynews.com/dpx-e7/DPX-Survivacfollowhttps://immuno-oncologynews.com/dpx-survivac/Enadenotucirevfollowhttps://immuno-oncologynews.com/enadenotucirev/EP-101 STEMVACfollowhttps://immuno-oncologynews.com/ep-101-stemvac/ETBX-011followhttps://immuno-oncologynews.com/etbx-011/ETBX-021followhttps://immuno-oncologynews.com/etbx-021/FAZ053followhttps://immuno-oncologynews.com/faz053/Flotetuzumab (MGD006)followhttps://immuno-oncologynews.com/flotetuzumab-mgd06/G-IfollowGALE-301followhttps://immuno-oncologynews.com/immuno-oncology-therapy-gale-301-is-designed-to-prevent-cancer-from-returning/Galinpepimut-Sfollowhttps://immuno-oncologynews.com/galinpepimut-s/Ganitumabfollowhttps://immuno-oncologynews.com/ganitumab/GBR 1342followhttps://immuno-oncologynews.com/gbr-1342/GI-6207followhttps://immuno-oncologynews.com/gi-6207/GI-6301followhttps://immuno-oncologynews.com/gi-6301/GL-ONC1followhttps://immuno-oncologynews.com/gl-onc1/Gliovac (ERC1671)followhttps://immuno-oncologynews.com/erc1671/GP2followhttps://immuno-oncologynews.com/gp2/GRN-1201followhttps://immuno-oncologynews.com/grn-1201/GSK3174998followhttps://immuno-oncologynews.com/gsk3174998/GWN323followhttps://immuno-oncologynews.com/gwn323/HF10followhttps://immuno-oncologynews.com/immuno-oncology-therapy-hf10-targets-melanoma/ICT-107followhttps://immuno-oncologynews.com/ict-107/ICT-121followhttps://immuno-oncologynews.com/ict-121/IGN002followhttps://immuno-oncologynews.com/ign002/IMCgp100followhttps://immuno-oncologynews.com/imcgp100/IMP701followhttps://immuno-oncologynews.com/imp701/INCAGN1949followhttps://immuno-oncologynews.com/incagn1949/INO-1400followhttps://immuno-oncologynews.com/ino-1400/INO-3106followhttps://immuno-oncologynews.com/ino-3106/INO-5150followhttps://immuno-oncologynews.com/ino-5150/INO-9012followhttps://immuno-oncologynews.com/ino9012/J-LfollowJCAR014followhttps://immuno-oncologynews.com/jcar014/JCAR017followhttps://immuno-oncologynews.com/jcar017/JNJ-61186372followhttps://immuno-oncologynews.com/jnj-61186372/JNJ-63709178followhttps://immuno-oncologynews.com/jnj-63709178/JNJ-63723283followhttps://immuno-oncologynews.com/io-jnj-63723283/JNJ-64041757 (ADU-214)followhttps://immuno-oncologynews.com/jnj-64041757-adu-214/JTX-2011followhttps://immuno-oncologynews.com/jtx-2011/KN035followhttps://immuno-oncologynews.com/io-kn035/LAG525 (IMP701)followhttps://immuno-oncologynews.com/lag525-imp701/LAMP-pp65-DC Vaccinefollowhttps://immuno-oncologynews.com/lamp-pp65-dc-vaccine/Lirilumab (IPH2102/BMS-986015)followhttps://immuno-oncologynews.com/lirilumab-iph2102bms-986015/LOAd703followhttps://immuno-oncologynews.com/load703/LV305followhttps://immuno-oncologynews.com/lv305/M-OfollowM7824followhttps://immuno-oncologynews.com/io-m7824/MAGE-A10 T-Cell Therapyfollowhttps://immuno-oncologynews.com/mage-a10-t-cell-therapy/MBG453followhttps://immuno-oncologynews.com/mbg453/MDNA55followhttps://immuno-oncologynews.com/mdna55/MEDI0457followhttps://immuno-oncologynews.com/medi0457/MEDI0562followhttps://immuno-oncologynews.com/medi0562/MEDI0680followhttps://immuno-oncologynews.com/medi0680/MGA012followhttps://immuno-oncologynews.com/mga-012/MGD009followhttps://immuno-oncologynews.com/mgd009/MK-4166followhttps://immuno-oncologynews.com/mk-4166/Mogamulizumabfollowhttps://immuno-oncologynews.com/mogamulizumab/MVA-BN Brachyuryfollowhttps://immuno-oncologynews.com/mva-bn-brachyury/MVI-118followhttps://immuno-oncologynews.com/mvi-118/NEO-PV-01followhttps://immuno-oncologynews.com/neo-pv-01/NeuVax (Nelipepimut-S)followhttps://immuno-oncologynews.com/neuvax-nelipepimut-s/NKR-2followhttps://immuno-oncologynews.com/nkr-2/NKTR-214followhttps://immuno-oncologynews.com/nktr-214/NY-ESO TCRfollowhttps://immuno-oncologynews.com/ny-eso-tcr/OncoVAXfollowhttps://immuno-oncologynews.com/oncovax/ONCOS-102followhttps://immuno-oncologynews.com/oncos-102/P-SfollowPAN-301-1followhttps://immuno-oncologynews.com/pan-301-1/PDR001followhttps://immuno-oncologynews.com/pdr001/PDS0101followhttps://immuno-oncologynews.com/pds0101/PF-04518600followhttps://immuno-oncologynews.com/pf-04518600/PF-06801591followhttps://immuno-oncologynews.com/pf-06801591/PNK-007followhttps://immuno-oncologynews.com/pnk-007/ProscaVaxfollowhttps://immuno-oncologynews.com/proscavax/Provenge (Sipuleucel-T)followhttps://immuno-oncologynews.com/provenge-sipuleucel-t/PVRIGfollowhttps://immuno-oncologynews.com/pvrig/REGN2810 (SAR439684)followhttps://immuno-oncologynews.com/regn2810/REGN3767followhttps://immuno-oncologynews.com/immuno-oncology-therapy-regn3767-fights-both-solid-tumors-and-blood-cancers/Relatlimabfollowhttps://immuno-oncologynews.com/relatlimab/Reolysinfollowhttps://immuno-oncologynews.com/reolysin/RG7802followhttps://immuno-oncologynews.com/rg7802/RG7828followhttps://immuno-oncologynews.com/rg7828/Rocapuldencel-Tfollowhttps://immuno-oncologynews.com/rocapuldencel-t/rSIFN-cofollowhttps://immuno-oncologynews.com/rsifn-co/SHR-1210followhttps://immuno-oncologynews.com/shr-1210/SL-701followhttps://immuno-oncologynews.com/sl-701/SurVaxMfollowhttps://immuno-oncologynews.com/survaxm-2/T-Zfollowhttp://1TT12followhttps://immuno-oncologynews.com/tt12/Tedopi (OSE-2101)followhttps://immuno-oncologynews.com/tedopi-ose-2101/Telomelysin (OBP-301)followhttps://immuno-oncologynews.com/telomelysin-obp-301/TG4010followhttps://immuno-oncologynews.com/tg4010/TPIV 200followhttps://immuno-oncologynews.com/tpiv-200/TPIV200followhttps://immuno-oncologynews.com/tpiv200/Traumakinefollowhttps://immuno-oncologynews.com/traumakine/TRX518followhttps://immuno-oncologynews.com/trx518/TSR-022followhttps://immuno-oncologynews.com/tsr-022/TSR-042followhttps://immuno-oncologynews.com/tsr-042/Utomilumabfollowhttps://immuno-oncologynews.com/utomilumab/ValloVaxfollowhttps://immuno-oncologynews.com/vallovax/Varlilumabfollowhttps://immuno-oncologynews.com/varlilumab/VBI-1901followhttps://immuno-oncologynews.com/vbi-1901-is-an-immuno-oncology-vaccine-for-two-types-of-brain-cancer/VGX-3100followhttps://immuno-oncologynews.com/vgx-3100-2/Viagenpumatucel-Lfollowhttps://immuno-oncologynews.com/viagenpumatucel-l/Vigilfollowhttps://immuno-oncologynews.com/vigil/VX15followhttps://immuno-oncologynews.com/vx15/XmAb13676followhttps://immuno-oncologynews.com/xmab13676/COVID-19 Infofollowhttps://immuno-oncologynews.com/information-about-covid-19-for-cancer-patients/COVID-19 Updatesfollowhttps://bionews.com/covid-19-weekly-updates/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in USfollowhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patientsfollowhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Imfinzi No Longer Available in US for Advanced Bladder Cancerfollowhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancersfollowhttps://immuno-oncologynews.com/2021/02/26/affimed-will-launch-trial-afm24-tecentriq-combo-egfr-positive-advanced-cancers/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancerfollowhttps://immuno-oncologynews.com/2021/02/24/tebentafusp-wins-fda-breakthrough-therapy-designation-advanced-eye-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancerfollowhttps://immuno-oncologynews.com/2021/02/22/keytruda-lenvima-combo-works-better-than-sutent-kidney-cancer-trial-results/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo Effective as Bladder Cancer Post-surgery Therapy, Data Showfollowhttps://immuno-oncologynews.com/2021/02/19/post-surgery-therapy-opdivo-advanced-bladder-cancer-phase-3-clinical-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FLX475 Shows Promising Safety, Anti-Tumor Activity; Trial Recruitingfollowhttps://immuno-oncologynews.com/2021/02/17/flx475-shows-promising-safety-anti-tumor-activity-certain-cancers-phase-1-2-trial-now-enrolling/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22followhttps://immuno-oncologynews.com/2021/02/15/biond-sanofi-partner-trial-immune-checkpoint-inhibitor-bnd-22-planned/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinomafollowhttps://immuno-oncologynews.com/2021/02/12/fda-approves-libtayo-first-immunotherapy-advanced-basal-cell-carcinoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomasfollowhttps://immuno-oncologynews.com/2021/02/10/car-t-cell-therapy-breyanzi-approved-large-b-cell-lymphomas/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Showfollowhttps://immuno-oncologynews.com/2021/02/08/yervoy-keytruda-combo-no-benefit-advanced-lung-cancer-keynote-598-phase-3-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumorsfollowhttps://immuno-oncologynews.com/2021/02/05/cytovia-nci-partner-develop-car-nk-cell-therapy-solid-tumors/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda Closer to Expanded EU Approval for Resistant Hodgkin’s Lymphomafollowhttps://immuno-oncologynews.com/2021/02/03/keytruda-approval-recommended-eu-relapsed-refractory-hodgkins-lymphoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/First Glioblastoma Patient Dosed in Phase 2 Trial Testing PVSRIPO Plus Keytrudafollowhttps://immuno-oncologynews.com/2021/02/01/first-glioblastoma-patient-dosed-phase-2-istari-trial-testing-pvsripo-plus-keytruda/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancersfollowhttps://immuno-oncologynews.com/2021/01/29/keytruda-approved-eu-first-line-treatment-advanced-colorectal-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Bavencio Approved in EU as First-line Maintenance Therapy for Bladder Cancerfollowhttps://immuno-oncologynews.com/2021/01/27/bavencio-approved-eu-first-line-maintenance-therapy-bladder-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancerfollowhttps://immuno-oncologynews.com/2021/01/25/retifanlimab-under-fda-priority-review-for-advanced-anal-canal-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancersfollowhttps://immuno-oncologynews.com/2021/01/22/fda-priority-review-opdivo-gastric-esophageal-cancers/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancerfollowhttps://immuno-oncologynews.com/2021/01/20/tecentriq-avastin-combination-continues-to-prolong-survival-in-advanced-liver-cancer-patients-updated-phase-3-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Less-frequent Dosing of Imfinzi Approved in Europe for Advanced Lung Cancerfollowhttps://immuno-oncologynews.com/2021/01/18/less-frequent-dosing-imfinzi-approved-europe-advanced-lung-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trialfollowhttps://immuno-oncologynews.com/2021/01/15/t-cell-therapy-adp-a2m4-showing-promise-synovial-sarcoma-phase-1-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancerfollowhttps://immuno-oncologynews.com/2021/01/11/aivita-biomedicals-personalized-av-gbm-1-cancer-vaccine-shows-promise-for-treating-gioblastoma-aggressive-brain-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reportsfollowhttps://immuno-oncologynews.com/2021/01/08/cavrotolimod-plus-pd-1-inhibitors-showing-efficacy-advanced-solid-tumors-phase-1b-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Statusfollowhttps://immuno-oncologynews.com/2021/01/06/tiragolumab-tecentriq-combo-for-nsclc-earns-breakthrough-therapy-status/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancerfollowhttps://immuno-oncologynews.com/2021/01/04/triple-immunotherapy-combo-including-libtayo-shows-promise-in-hard-to-treat-brain-cancer-early-data-suggest/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapyfollowhttps://immuno-oncologynews.com/2020/12/21/io102-io103-cancer-vaccines-get-fda-breakthrough-status-in-advanced-melanoma-combo-therapy/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tebentafusp Prolongs Life for Those With Advanced Eye Cancer, Trial Findsfollowhttps://immuno-oncologynews.com/2020/12/18/immunocore-tebentafusp-seen-prolong-life-advanced-eye-cancer-patients-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/EU Approval Urged for Bavencio as Maintenance Therapy for Bladder Cancerfollowhttps://immuno-oncologynews.com/2020/12/16/ema-committee-recommends-eu-approval-bavencio-as-initial-maintenance-treatment-for-bladder-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda Approval Recommended in EU as First-line Therapy for Certain Colorectal Cancersfollowhttps://immuno-oncologynews.com/2020/12/14/keytruda-approval-recommended-in-eu-as-first-line-therapy-for-certain-advanced-colorectal-cancers/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Yescarta Shows Promise in Advanced Non-Hodgkin Lymphomas, Trial Data Showfollowhttps://immuno-oncologynews.com/2020/12/11/yescarta-shows-promise-in-advanced-non-hodgkin-lymphomas-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Showfollowhttps://immuno-oncologynews.com/2020/12/09/tislelizumab-safely-prolongs-survival-advanced-lung-cancer-patients-interim-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancerfollowhttps://immuno-oncologynews.com/2020/12/07/fda-approves-less-frequent-regimen-imfinzi-nsclc-bladder-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda-Lenvima Combo in Kidney Cancer Better Than Sutent in Improving Survivalfollowhttps://immuno-oncologynews.com/2020/12/04/keytruda-lenvima-combo-in-advanced-kidney-cancer-better-than-sutent-in-improving-survival-outcomes-top-line-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancerfollowhttps://immuno-oncologynews.com/2020/11/30/opdivo-approved-europe-second-line-therapy-advanced-esophageal-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancerfollowhttps://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/syndicatedfollowhttps://immuno-oncologynews.com/category/syndicated/New $100M Program Aims to Improve Diversity in Clinical Trialsfollowhttps://immuno-oncologynews.com/2020/11/23/new-100m-program-aims-to-improve-diversity-in-clinical-trials/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Clinical Trial to Test CRISPR-modified T-cells in Treating Advanced Cancersfollowhttps://immuno-oncologynews.com/2020/11/20/clinical-trial-to-evaluate-crispr-modified-t-cells-as-potential-advanced-cancer-treatment/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Phase 3 Study of Epcoritamab for Advanced DLBCL to Open in Europe, Australiafollowhttps://immuno-oncologynews.com/2020/11/18/phase-3-study-epcoritamab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-opening/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda-Chemo Combo Improves Survival Outcomes in Advanced Lung Cancerfollowhttps://immuno-oncologynews.com/2020/11/13/keytruda-chemo-combo-improves-survival-outcomes-in-advanced-lung-cancer-patients-trial-shows/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Post-surgery Opdivo Found to Reduce Risk of Recurrence in High-risk Bladder Cancerfollowhttps://immuno-oncologynews.com/2020/11/11/post-surgery-opdivo-found-to-reduce-risk-of-recurrence-in-high-risk-bladder-cancer-checkmate-274-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo-Yervoy-Chemo Combo Approved in EU for Advanced NSCLCfollowhttps://immuno-oncologynews.com/2020/11/09/opdivo-yervoy-chemo-combo-approved-eu-advanced-nsclc/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tecentriq-Avastin Combo Approved in Europe for Advanced or Inoperable Liver Cancerfollowhttps://immuno-oncologynews.com/2020/11/06/tecentriq-avastin-combo-approved-europe-to-treat-advanced-or-inoperable-liver-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levelsfollowhttps://immuno-oncologynews.com/2020/11/02/libtayo-given-fda-priority-review-for-advanced-nsclc-with-high-pd-l1-levels/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Nearly Half of Imfinzi-treated NSCLC Patients Alive After 4 Years, PACIFIC Update Showsfollowhttps://immuno-oncologynews.com/2020/10/30/nearly-half-of-imfinzi-treated-nsclc-patients-alive-after-4-years-pacific-update-shows/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancersfollowhttps://immuno-oncologynews.com/2020/10/28/opdivo-combo-extends-survival-advanced-stomach-and-esophageal-cancers-phase-3-trial-shows/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo-Cabometyx Granted FDA Priority Review for Newly Diagnosed Advanced Kidney Cancerfollowhttps://immuno-oncologynews.com/2020/10/26/opdivo-cabometyx-combo-granted-fda-priority-review-newly-diagnosed-advanced-kidney-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trialfollowhttps://immuno-oncologynews.com/2020/10/23/cancer-vaccine-uv1-keytruda-combo-shows-safety-early-effective-advanced-melanoma-phase-1-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Committee Recommends EU Approval of Opdivo to Treat Advanced Esophageal Cancerfollowhttps://immuno-oncologynews.com/2020/10/21/opdivo-recommended-for-eu-approval-to-treat-advanced-esophageal-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymphomafollowhttps://immuno-oncologynews.com/2020/10/19/chmp-favors-eu-conditional-approval-car-t-cell-therapy-tecartus-mantle-cell-lymphoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Keytruda for Adults as Second-Line Therapy for Hodgkin’s Lymphomafollowhttps://immuno-oncologynews.com/2020/10/16/fda-approves-keytruda-as-second-line-therapy-relapsed-or-refractory-classical-hodgkins-lymphoma-updates-indication-children-adolescents/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Enrollment Underway in Melanoma Trial Testing Leukine Triple Combofollowhttps://immuno-oncologynews.com/2020/10/14/enrollment-underway-phase-3-trial-testing-leukine-yervoy-opdivo-combo-treatment-for-advanced-melanoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Agenus Begins Rolling Submission of Balstilimab to FDA for Advanced Cervical Cancerfollowhttps://immuno-oncologynews.com/2020/10/12/agenus-begins-rolling-submission-of-balstilimab-to-fda-advanced-cervical-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Opdivo-Yervoy Combo as First-Line Therapy for Inoperable Mesotheliomafollowhttps://immuno-oncologynews.com/2020/10/09/fda-approves-opdivo-yervoy-combo-as-first-line-therapy-for-inoperable-mesothelioma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Phase 1 Trial of ET140203 T-cell Therapy Starts Enrolling Adults With Advanced Liver Cancerfollowhttps://immuno-oncologynews.com/2020/10/07/phase-1-trial-of-et140203-t-cell-therapy-starts-enrolling-adults-with-advanced-liver-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Libtayo First-line Treatment Prolongs Survival in Advanced NSCLC, Early Trial Data Showfollowhttps://immuno-oncologynews.com/2020/10/02/libtayo-first-line-treatment-prolongs-survival-among-advanced-lung-cancer-nsclc-patients-phase-3-trial-shows/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda Combo Shown to Extend Survival in Advanced Esophageal, GEJ Cancersfollowhttps://immuno-oncologynews.com/2020/09/30/first-line-keytruda-combo-extends-survival-delays-disease-progression-or-death-in-advanced-esophageal-gej-cancers-phase-3-trial-shows/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/First-line Keytruda Doubles 5-Year Survival in Certain Lung Cancer Patients, Data Showfollowhttps://immuno-oncologynews.com/2020/09/28/first-line-keytruda-doubles-5-year-survival-in-certain-lung-cancer-patients-keynote-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tecentriq-Avastin Combo Recommended for EU Approval for Liver Cancerfollowhttps://immuno-oncologynews.com/2020/09/25/tecentriq-avastin-combo-recommended-for-eu-approval-for-newly-diagnosed-advanced-liver-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/EU Approval Recommended for Opdivo-Yervoy-Chemo Combo for Advanced NSCLCfollowhttps://immuno-oncologynews.com/2020/09/23/opdivo-yervoy-chemo-combo-recommended-for-eu-approval-for-advanced-nsclc/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Acts to Speed Toripalimab as Potential Nasopharyngeal Cancer Treatmentfollowhttps://immuno-oncologynews.com/2020/09/21/fda-names-toripalimab-breakthrough-therapy-potential-nasopharyngeal-cancer-treatment/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/EMA to Review Opdivo-Yervoy Combo for Untreated, Inoperable Mesotheliomafollowhttps://immuno-oncologynews.com/2020/09/18/ema-to-review-opdivo-yervoy-combo-for-untreated-inoperable-mesothelioma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Post-surgery Opdivo Shows Benefits for Esophageal, GEJ Cancer Patients in Ongoing Trialfollowhttps://immuno-oncologynews.com/2020/09/14/post-surgery-opdivo-shows-benefits-for-esophageal-gej-cancer-patients-in-ongoing-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trialfollowhttps://immuno-oncologynews.com/2020/09/09/tessas-cd30-car-t-cell-therapy-safe-leads-to-strong-durable-responses-hodgkins-lymphoma-phase-1-2-trials-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for Liver Cancerfollowhttps://immuno-oncologynews.com/2020/09/04/fda-rejects-keytruda-lenvima-combo-as-first-line-treatment-for-liver-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Imfinzi Approved in EU for Extensive-stage Small Cell Lung Cancerfollowhttps://immuno-oncologynews.com/2020/09/02/imfinzi-approved-european-union-for-extensive-stage-small-cell-lung-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Imfinzi as Once Monthly NSCLC, Bladder Cancer Treatment Under FDA Reviewfollowhttps://immuno-oncologynews.com/2020/08/31/imfinzi-as-once-monthly-nsclc-bladder-cancer-treatment-under-fda-review/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Novocure, MSD Team Up to Test TTFields-Keytruda Combo in Lung Cancerfollowhttps://immuno-oncologynews.com/2020/08/26/novocure-msd-team-up-on-lung-cancer-clinical-trial-testing-ttfields-keytruda-combo/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Health Canada Approves Opdivo-Yervoy-Chemo Combo for Advanced NSCLCfollowhttps://immuno-oncologynews.com/2020/08/17/health-canada-approves-opdivo-yervoy-chemo-combo-for-advanced-nsclc/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo-Yervoy Combo Prolongs Survival of Patients With Inoperable Mesothelioma, Phase 3 Trial Showsfollowhttps://immuno-oncologynews.com/2020/08/12/opdivo-yervoy-combo-prolongs-survival-of-patients-with-inoperable-mesothelioma-phase-3-trial-shows/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Clears FT819 CAR T-cell Therapy for Clinical Testing in Lymphoma, Leukemiafollowhttps://immuno-oncologynews.com/2020/08/07/fda-clears-fates-ft819-car-t-cell-therapy-for-clinical-testing-in-lymphoma-leukemia/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Tecentriq Combo for Certain Advanced Melanomasfollowhttps://immuno-oncologynews.com/2020/08/03/fda-approves-tecentriq-cotellic-and-zelboraf-for-certain-advanced-melanomas/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Yale Researcher Wins NIH Merit Award, Supporting Immunotherapy Workfollowhttps://immuno-oncologynews.com/2020/07/31/yale-researcher-wins-r37-merit-away-nih-support-immunotherapy-work/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/CAR T-cell Therapy Tecartus Granted FDA Approval for Mantle Cell Lymphomafollowhttps://immuno-oncologynews.com/2020/07/28/car-t-cell-therapy-tecartus-granted-fda-approval-for-mantle-cell-lymphoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Phase 3 Trial Launched to Test Cabometyx-Tecentriq in Advanced Kidney Cancerfollowhttps://immuno-oncologynews.com/2020/07/27/exelixis-launches-phase-3-trial-testing-cabometyx-tecentriq-combo-in-advanced-kidney-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/New Light-activated CAR T-cells May Help Reduce Therapy Side Effectsfollowhttps://immuno-oncologynews.com/2020/07/24/light-activated-car-t-cells-may-help-reduce-cancer-therapy-side-effects/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/EMA to Review Liso-cel as CAR T-cell Therapy for Advanced Lymphomasfollowhttps://immuno-oncologynews.com/2020/07/22/ema-reviewing-liso-cell-car-t-cell-therapy-for-relapsed-refractory-lymphomas/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Imfinzi Plus Chemo Aids Survival in Inoperable Pleural Mesothelioma, Phase 2 Data Showfollowhttps://immuno-oncologynews.com/2020/07/20/imfinzi-plus-chemo-aids-survival-in-inoperable-pleural-mesothelioma-phase-2-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Grants Priority Review to Keytruda for Relapsed or Refractory Classical Hodgkin’s Lymphomafollowhttps://immuno-oncologynews.com/2020/07/17/fda-grants-priority-review-keytruda-relapsed-refratory-classical-hodgkins-lymphoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Uppsala in Last Preclinical Stage for New CAR T-cell Product for Glioblastomafollowhttps://immuno-oncologynews.com/2020/07/15/uppsala-university-in-last-preclinical-stage-new-car-t-cell-product-glioblastoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLCfollowhttps://immuno-oncologynews.com/2020/07/06/first-line-tislelizumab-plus-chemo-under-review-china-advanced-nsclc/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancerfollowhttps://immuno-oncologynews.com/2020/07/02/advanced-bladder-cancer-maintenance-therapy-bavencio-approved-by-fda/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancersfollowhttps://immuno-oncologynews.com/2020/07/01/fda-approves-keytruda-first-line-therapy-certain-advanced-colorectal-cancers/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/syndicatedfollowhttps://immuno-oncologynews.com/category/syndicated/FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trialsfollowhttps://immuno-oncologynews.com/2020/06/30/new-fda-program-project-patient-voice-will-share-patient-reported-outcomes-from-cancer-clinical-trials/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/EMA Asked to Conditionally Approve Gliovac, Cancer Vaccine, for Recurrent Glioblastomafollowhttps://immuno-oncologynews.com/2020/06/29/erc-belgium-asks-ema-conditional-approval-gliovac-cancer-vaccine-recurrent-gliobastoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Keytruda for Advanced Squamous Cell Skin Cancerfollowhttps://immuno-oncologynews.com/2020/06/26/fda-approves-keytruda-treatment-advanced-squamous-cell-skin-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda Approved in China as Second-line Therapy for Advanced Esophageal Cancersfollowhttps://immuno-oncologynews.com/2020/06/24/keytruda-approved-china-second-line-therapy-advanced-esophageal-cancers/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Imfinzi Plus Chemo Showing 2-year Survival Benefit in Advanced SCLC Studyfollowhttps://immuno-oncologynews.com/2020/06/22/imfinzi-chemo-combo-as-initial-therapy-showing-2-year-survival-benefit-sclc-study/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda Approved to Treat Solid Tumors With High Mutational Burdenfollowhttps://immuno-oncologynews.com/2020/06/18/keytruda-approved-to-treat-solid-tumors-with-high-mutational-burden/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Bavencio Shows Benefit as 1st-line Maintenance Therapy for Bladder Cancer in Phase 3 Trialfollowhttps://immuno-oncologynews.com/2020/06/17/bavencio-shows-benefit-first-line-maintenance-therapy-advanced-bladder-cancer-phase-3-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Trackfollowhttps://immuno-oncologynews.com/2020/06/15/cancer-vaccine-adoptive-t-cell-therapy-tvi-brain-1-placed-fast-track/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Opdivo for Advanced Esophageal Cancerfollowhttps://immuno-oncologynews.com/2020/06/12/fda-approves-opdivo-for-advanced-esophageal-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tislelizumab-Chemo Combo Does Well in Advanced Squamous NSCLC Trialfollowhttps://immuno-oncologynews.com/2020/06/05/tislelizumab-chemo-combo-does-well-in-advanced-squamous-nsclc-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancerfollowhttps://immuno-oncologynews.com/2020/06/03/fda-approves-tecentriq-avastin-newly-diagnosed-advanced-hepatocellular-carcinoma-liver-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Surface, Merck Partner on SRF617-Keytruda Combo Targeting Solid Tumorsfollowhttps://immuno-oncologynews.com/2020/06/01/surface-merck-partner-srf617-keytruda-combo-targeting-solid-tumors/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/ONCOS-102 Plus Chemo Showing Sustained Benefit in Mesothelioma Trialfollowhttps://immuno-oncologynews.com/2020/05/26/oncos-102-plus-chemo-showing-sustained-benefit-phase-2-mesothelioma-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Tecentriq as Initial Treatment for Advanced NSCLCfollowhttps://immuno-oncologynews.com/2020/05/20/fda-approves-tecentriq-as-initial-treatment-for-advanced-nsclc/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Opdivo-Yervoy Combo for First-line Treatment of Advanced NSCLCfollowhttps://immuno-oncologynews.com/2020/05/19/fda-approves-opdivo-yervoy-combo-first-line-treatment-advanced-nsclc/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/ICT’s CAR T-cell Therapy Shows Promise in Reducing Size of Solid Tumorsfollowhttps://immuno-oncologynews.com/2020/05/12/innovative-cellular-therapeutics-car-t-cell-therapy-shows-promise-for-solid-tumors/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Dostarlimab Shows Promise for Advanced Endometrial Cancer, Early Trial Results Showfollowhttps://immuno-oncologynews.com/2020/05/05/dostarlimab-shows-promise-for-advanced-endometrial-cancer-phase-1-trial-finds/followhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/followhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/March 5, 2021March 5, 2021followhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously ... Read morefollowhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/Read morefollowhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/followhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/followhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/March 3, 2021March 3, 2021followhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients A combination of ilixadencel plus first-line treatment with Sutent (sunitinib) prolonged overall survival to a clinically meaningful extent in newly diagnosed patients with metastatic renal cell ... Read morefollowhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/Read morefollowhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/followhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/followhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/March 1, 2021March 1, 2021followhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/Imfinzi No Longer Available in US for Advanced Bladder Cancer After consulting with the U.S. Food and Drug Administration (FDA), AstraZeneca has announced that Imfinzi (durvalumab) — which last year failed a confirmatory Phase 3 ... Read morefollowhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/Read morefollowhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/followhttps://immuno-oncologynews.com/2021/02/26/affimed-will-launch-trial-afm24-tecentriq-combo-egfr-positive-advanced-cancers/followhttps://immuno-oncologynews.com/2021/02/26/affimed-will-launch-trial-afm24-tecentriq-combo-egfr-positive-advanced-cancers/February 26, 2021February 26, 2021followhttps://immuno-oncologynews.com/2021/02/26/affimed-will-launch-trial-afm24-tecentriq-combo-egfr-positive-advanced-cancers/Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancers Affimed will team up with Roche to conduct a Phase 1/2a clinical trial investigating its innate cell engager AFM24 — a form of immunotherapy — ... Read morefollowhttps://immuno-oncologynews.com/2021/02/26/affimed-will-launch-trial-afm24-tecentriq-combo-egfr-positive-advanced-cancers/Read morefollowhttps://immuno-oncologynews.com/2021/02/26/affimed-will-launch-trial-afm24-tecentriq-combo-egfr-positive-advanced-cancers/followhttps://immuno-oncologynews.com/2021/02/24/tebentafusp-wins-fda-breakthrough-therapy-designation-advanced-eye-cancer/followhttps://immuno-oncologynews.com/2021/02/24/tebentafusp-wins-fda-breakthrough-therapy-designation-advanced-eye-cancer/February 24, 2021February 24, 2021followhttps://immuno-oncologynews.com/2021/02/24/tebentafusp-wins-fda-breakthrough-therapy-designation-advanced-eye-cancer/Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a ... Read morefollowhttps://immuno-oncologynews.com/2021/02/24/tebentafusp-wins-fda-breakthrough-therapy-designation-advanced-eye-cancer/Read morefollowhttps://immuno-oncologynews.com/2021/02/24/tebentafusp-wins-fda-breakthrough-therapy-designation-advanced-eye-cancer/followhttps://immuno-oncologynews.com/2021/02/22/keytruda-lenvima-combo-works-better-than-sutent-kidney-cancer-trial-results/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancerfollowhttps://immuno-oncologynews.com/2021/02/22/keytruda-lenvima-combo-works-better-than-sutent-kidney-cancer-trial-results/February 22, 2021February 22, 2021followhttps://immuno-oncologynews.com/2021/02/22/keytruda-lenvima-combo-works-better-than-sutent-kidney-cancer-trial-results/followhttps://immuno-oncologynews.com/2021/02/22/keytruda-lenvima-combo-works-better-than-sutent-kidney-cancer-trial-results/A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) at ...followhttps://immuno-oncologynews.com/2021/02/22/keytruda-lenvima-combo-works-better-than-sutent-kidney-cancer-trial-results/followhttps://immuno-oncologynews.com/2021/02/19/post-surgery-therapy-opdivo-advanced-bladder-cancer-phase-3-clinical-trial/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo Effective as Bladder Cancer Post-surgery Therapy, Data Showfollowhttps://immuno-oncologynews.com/2021/02/19/post-surgery-therapy-opdivo-advanced-bladder-cancer-phase-3-clinical-trial/February 19, 2021February 19, 2021followhttps://immuno-oncologynews.com/2021/02/19/post-surgery-therapy-opdivo-advanced-bladder-cancer-phase-3-clinical-trial/followhttps://immuno-oncologynews.com/2021/02/19/post-surgery-therapy-opdivo-advanced-bladder-cancer-phase-3-clinical-trial/Treatment with Opdivo (nivolumab) after surgery significantly delays disease recurrence or death in patients with ...followhttps://immuno-oncologynews.com/2021/02/19/post-surgery-therapy-opdivo-advanced-bladder-cancer-phase-3-clinical-trial/followhttps://immuno-oncologynews.com/2021/02/17/flx475-shows-promising-safety-anti-tumor-activity-certain-cancers-phase-1-2-trial-now-enrolling/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FLX475 Shows Promising Safety, Anti-Tumor Activity; Trial Recruitingfollowhttps://immuno-oncologynews.com/2021/02/17/flx475-shows-promising-safety-anti-tumor-activity-certain-cancers-phase-1-2-trial-now-enrolling/February 17, 2021February 17, 2021followhttps://immuno-oncologynews.com/2021/02/17/flx475-shows-promising-safety-anti-tumor-activity-certain-cancers-phase-1-2-trial-now-enrolling/followhttps://immuno-oncologynews.com/2021/02/17/flx475-shows-promising-safety-anti-tumor-activity-certain-cancers-phase-1-2-trial-now-enrolling/FLX475, an investigational anti-cancer therapy by RAPT Therapeutics, is safe and shows promising anti-tumor clinical ...followhttps://immuno-oncologynews.com/2021/02/17/flx475-shows-promising-safety-anti-tumor-activity-certain-cancers-phase-1-2-trial-now-enrolling/followhttps://immuno-oncologynews.com/2021/02/15/biond-sanofi-partner-trial-immune-checkpoint-inhibitor-bnd-22-planned/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22followhttps://immuno-oncologynews.com/2021/02/15/biond-sanofi-partner-trial-immune-checkpoint-inhibitor-bnd-22-planned/February 15, 2021February 15, 2021followhttps://immuno-oncologynews.com/2021/02/15/biond-sanofi-partner-trial-immune-checkpoint-inhibitor-bnd-22-planned/followhttps://immuno-oncologynews.com/2021/02/15/biond-sanofi-partner-trial-immune-checkpoint-inhibitor-bnd-22-planned/Biond Biologics and Sanofi have entered into a worldwide licensing agreement to advance BND-22, a ...followhttps://immuno-oncologynews.com/2021/02/15/biond-sanofi-partner-trial-immune-checkpoint-inhibitor-bnd-22-planned/followhttps://immuno-oncologynews.com/2021/02/12/fda-approves-libtayo-first-immunotherapy-advanced-basal-cell-carcinoma/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinomafollowhttps://immuno-oncologynews.com/2021/02/12/fda-approves-libtayo-first-immunotherapy-advanced-basal-cell-carcinoma/February 12, 2021February 12, 2021followhttps://immuno-oncologynews.com/2021/02/12/fda-approves-libtayo-first-immunotherapy-advanced-basal-cell-carcinoma/followhttps://immuno-oncologynews.com/2021/02/12/fda-approves-libtayo-first-immunotherapy-advanced-basal-cell-carcinoma/The U.S. Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc), making it the first ...followhttps://immuno-oncologynews.com/2021/02/12/fda-approves-libtayo-first-immunotherapy-advanced-basal-cell-carcinoma/followhttps://immuno-oncologynews.com/2021/02/10/car-t-cell-therapy-breyanzi-approved-large-b-cell-lymphomas/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomasfollowhttps://immuno-oncologynews.com/2021/02/10/car-t-cell-therapy-breyanzi-approved-large-b-cell-lymphomas/February 10, 2021February 10, 2021followhttps://immuno-oncologynews.com/2021/02/10/car-t-cell-therapy-breyanzi-approved-large-b-cell-lymphomas/followhttps://immuno-oncologynews.com/2021/02/10/car-t-cell-therapy-breyanzi-approved-large-b-cell-lymphomas/The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Breyanzi (lisocabtagene ...followhttps://immuno-oncologynews.com/2021/02/10/car-t-cell-therapy-breyanzi-approved-large-b-cell-lymphomas/followhttps://immuno-oncologynews.com/2021/02/08/yervoy-keytruda-combo-no-benefit-advanced-lung-cancer-keynote-598-phase-3-trial/Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Showfollowhttps://immuno-oncologynews.com/2021/02/08/yervoy-keytruda-combo-no-benefit-advanced-lung-cancer-keynote-598-phase-3-trial/February 8, 2021February 8, 2021followhttps://immuno-oncologynews.com/2021/02/08/yervoy-keytruda-combo-no-benefit-advanced-lung-cancer-keynote-598-phase-3-trial/followhttps://immuno-oncologynews.com/2021/02/08/yervoy-keytruda-combo-no-benefit-advanced-lung-cancer-keynote-598-phase-3-trial/First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival ...followhttps://immuno-oncologynews.com/2021/02/08/yervoy-keytruda-combo-no-benefit-advanced-lung-cancer-keynote-598-phase-3-trial/followhttps://immuno-oncologynews.com/2021/02/05/cytovia-nci-partner-develop-car-nk-cell-therapy-solid-tumors/Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumorsfollowhttps://immuno-oncologynews.com/2021/02/05/cytovia-nci-partner-develop-car-nk-cell-therapy-solid-tumors/February 5, 2021February 5, 2021followhttps://immuno-oncologynews.com/2021/02/05/cytovia-nci-partner-develop-car-nk-cell-therapy-solid-tumors/followhttps://immuno-oncologynews.com/2021/02/05/cytovia-nci-partner-develop-car-nk-cell-therapy-solid-tumors/Cytovia Therapeutics has entered into a licensing agreement with the National Cancer Institute (NCI) to ...followhttps://immuno-oncologynews.com/2021/02/05/cytovia-nci-partner-develop-car-nk-cell-therapy-solid-tumors/followhttps://immuno-oncologynews.com/2021/02/03/keytruda-approval-recommended-eu-relapsed-refractory-hodgkins-lymphoma/Keytruda Closer to Expanded EU Approval for Resistant Hodgkin’s Lymphomafollowhttps://immuno-oncologynews.com/2021/02/03/keytruda-approval-recommended-eu-relapsed-refractory-hodgkins-lymphoma/February 3, 2021February 3, 2021followhttps://immuno-oncologynews.com/2021/02/03/keytruda-approval-recommended-eu-relapsed-refractory-hodgkins-lymphoma/followhttps://immuno-oncologynews.com/2021/02/03/keytruda-approval-recommended-eu-relapsed-refractory-hodgkins-lymphoma/followhttps://immuno-oncologynews.com/2021/02/01/first-glioblastoma-patient-dosed-phase-2-istari-trial-testing-pvsripo-plus-keytruda/First Glioblastoma Patient Dosed in Phase 2 Trial Testing PVSRIPO Plus Keytrudafollowhttps://immuno-oncologynews.com/2021/02/01/first-glioblastoma-patient-dosed-phase-2-istari-trial-testing-pvsripo-plus-keytruda/February 1, 2021February 1, 2021followhttps://immuno-oncologynews.com/2021/02/01/first-glioblastoma-patient-dosed-phase-2-istari-trial-testing-pvsripo-plus-keytruda/followhttps://immuno-oncologynews.com/2021/02/01/first-glioblastoma-patient-dosed-phase-2-istari-trial-testing-pvsripo-plus-keytruda/followhttps://immuno-oncologynews.com/2021/01/29/keytruda-approved-eu-first-line-treatment-advanced-colorectal-cancer/EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancersfollowhttps://immuno-oncologynews.com/2021/01/29/keytruda-approved-eu-first-line-treatment-advanced-colorectal-cancer/January 29, 2021January 29, 2021followhttps://immuno-oncologynews.com/2021/01/29/keytruda-approved-eu-first-line-treatment-advanced-colorectal-cancer/followhttps://immuno-oncologynews.com/2021/01/29/keytruda-approved-eu-first-line-treatment-advanced-colorectal-cancer/followhttps://immuno-oncologynews.com/2021/01/27/bavencio-approved-eu-first-line-maintenance-therapy-bladder-cancer/Bavencio Approved in EU as First-line Maintenance Therapy for Bladder Cancerfollowhttps://immuno-oncologynews.com/2021/01/27/bavencio-approved-eu-first-line-maintenance-therapy-bladder-cancer/January 27, 2021January 27, 2021followhttps://immuno-oncologynews.com/2021/01/27/bavencio-approved-eu-first-line-maintenance-therapy-bladder-cancer/followhttps://immuno-oncologynews.com/2021/01/27/bavencio-approved-eu-first-line-maintenance-therapy-bladder-cancer/followhttps://immuno-oncologynews.com/2021/01/25/retifanlimab-under-fda-priority-review-for-advanced-anal-canal-cancer/Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancerfollowhttps://immuno-oncologynews.com/2021/01/25/retifanlimab-under-fda-priority-review-for-advanced-anal-canal-cancer/January 25, 2021January 25, 2021followhttps://immuno-oncologynews.com/2021/01/25/retifanlimab-under-fda-priority-review-for-advanced-anal-canal-cancer/followhttps://immuno-oncologynews.com/2021/01/25/retifanlimab-under-fda-priority-review-for-advanced-anal-canal-cancer/Retifanlimab is under review in the U.S. as a treatment for advanced squamous cell carcinoma ...followhttps://immuno-oncologynews.com/2021/01/25/retifanlimab-under-fda-priority-review-for-advanced-anal-canal-cancer/followhttps://immuno-oncologynews.com/2021/01/22/fda-priority-review-opdivo-gastric-esophageal-cancers/FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancersfollowhttps://immuno-oncologynews.com/2021/01/22/fda-priority-review-opdivo-gastric-esophageal-cancers/January 22, 2021January 22, 2021followhttps://immuno-oncologynews.com/2021/01/22/fda-priority-review-opdivo-gastric-esophageal-cancers/followhttps://immuno-oncologynews.com/2021/01/22/fda-priority-review-opdivo-gastric-esophageal-cancers/followhttps://immuno-oncologynews.com/2021/01/20/tecentriq-avastin-combination-continues-to-prolong-survival-in-advanced-liver-cancer-patients-updated-phase-3-trial-data-show/Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancerfollowhttps://immuno-oncologynews.com/2021/01/20/tecentriq-avastin-combination-continues-to-prolong-survival-in-advanced-liver-cancer-patients-updated-phase-3-trial-data-show/January 20, 2021January 20, 2021followhttps://immuno-oncologynews.com/2021/01/20/tecentriq-avastin-combination-continues-to-prolong-survival-in-advanced-liver-cancer-patients-updated-phase-3-trial-data-show/followhttps://immuno-oncologynews.com/2021/01/20/tecentriq-avastin-combination-continues-to-prolong-survival-in-advanced-liver-cancer-patients-updated-phase-3-trial-data-show/followhttps://immuno-oncologynews.com/2021/01/18/less-frequent-dosing-imfinzi-approved-europe-advanced-lung-cancer/Less-frequent Dosing of Imfinzi Approved in Europe for Advanced Lung Cancerfollowhttps://immuno-oncologynews.com/2021/01/18/less-frequent-dosing-imfinzi-approved-europe-advanced-lung-cancer/January 18, 2021January 18, 2021followhttps://immuno-oncologynews.com/2021/01/18/less-frequent-dosing-imfinzi-approved-europe-advanced-lung-cancer/followhttps://immuno-oncologynews.com/2021/01/18/less-frequent-dosing-imfinzi-approved-europe-advanced-lung-cancer/followhttps://immuno-oncologynews.com/2021/01/15/t-cell-therapy-adp-a2m4-showing-promise-synovial-sarcoma-phase-1-trial/T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trialfollowhttps://immuno-oncologynews.com/2021/01/15/t-cell-therapy-adp-a2m4-showing-promise-synovial-sarcoma-phase-1-trial/January 15, 2021January 15, 2021followhttps://immuno-oncologynews.com/2021/01/15/t-cell-therapy-adp-a2m4-showing-promise-synovial-sarcoma-phase-1-trial/followhttps://immuno-oncologynews.com/2021/01/15/t-cell-therapy-adp-a2m4-showing-promise-synovial-sarcoma-phase-1-trial/ADP-A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable ...followhttps://immuno-oncologynews.com/2021/01/15/t-cell-therapy-adp-a2m4-showing-promise-synovial-sarcoma-phase-1-trial/followhttps://immuno-oncologynews.com/2021/01/11/aivita-biomedicals-personalized-av-gbm-1-cancer-vaccine-shows-promise-for-treating-gioblastoma-aggressive-brain-cancer/Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancerfollowhttps://immuno-oncologynews.com/2021/01/11/aivita-biomedicals-personalized-av-gbm-1-cancer-vaccine-shows-promise-for-treating-gioblastoma-aggressive-brain-cancer/January 11, 2021January 11, 2021followhttps://immuno-oncologynews.com/2021/01/11/aivita-biomedicals-personalized-av-gbm-1-cancer-vaccine-shows-promise-for-treating-gioblastoma-aggressive-brain-cancer/followhttps://immuno-oncologynews.com/2021/01/11/aivita-biomedicals-personalized-av-gbm-1-cancer-vaccine-shows-promise-for-treating-gioblastoma-aggressive-brain-cancer/followhttps://immuno-oncologynews.com/2021/01/08/cavrotolimod-plus-pd-1-inhibitors-showing-efficacy-advanced-solid-tumors-phase-1b-trial/Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reportsfollowhttps://immuno-oncologynews.com/2021/01/08/cavrotolimod-plus-pd-1-inhibitors-showing-efficacy-advanced-solid-tumors-phase-1b-trial/January 8, 2021January 8, 2021followhttps://immuno-oncologynews.com/2021/01/08/cavrotolimod-plus-pd-1-inhibitors-showing-efficacy-advanced-solid-tumors-phase-1b-trial/followhttps://immuno-oncologynews.com/2021/01/08/cavrotolimod-plus-pd-1-inhibitors-showing-efficacy-advanced-solid-tumors-phase-1b-trial/followhttps://immuno-oncologynews.com/2021/01/06/tiragolumab-tecentriq-combo-for-nsclc-earns-breakthrough-therapy-status/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Statusfollowhttps://immuno-oncologynews.com/2021/01/06/tiragolumab-tecentriq-combo-for-nsclc-earns-breakthrough-therapy-status/January 6, 2021January 6, 2021followhttps://immuno-oncologynews.com/2021/01/06/tiragolumab-tecentriq-combo-for-nsclc-earns-breakthrough-therapy-status/followhttps://immuno-oncologynews.com/2021/01/06/tiragolumab-tecentriq-combo-for-nsclc-earns-breakthrough-therapy-status/The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to ...followhttps://immuno-oncologynews.com/2021/01/06/tiragolumab-tecentriq-combo-for-nsclc-earns-breakthrough-therapy-status/followhttps://immuno-oncologynews.com/2021/01/04/triple-immunotherapy-combo-including-libtayo-shows-promise-in-hard-to-treat-brain-cancer-early-data-suggest/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancerfollowhttps://immuno-oncologynews.com/2021/01/04/triple-immunotherapy-combo-including-libtayo-shows-promise-in-hard-to-treat-brain-cancer-early-data-suggest/January 4, 2021January 8, 2021followhttps://immuno-oncologynews.com/2021/01/04/triple-immunotherapy-combo-including-libtayo-shows-promise-in-hard-to-treat-brain-cancer-early-data-suggest/followhttps://immuno-oncologynews.com/2021/01/04/triple-immunotherapy-combo-including-libtayo-shows-promise-in-hard-to-treat-brain-cancer-early-data-suggest/Combining two experimental cancer vaccines with Libtayo (cemiplimab) promotes strong anti-tumor immune responses and shows ...followhttps://immuno-oncologynews.com/2021/01/04/triple-immunotherapy-combo-including-libtayo-shows-promise-in-hard-to-treat-brain-cancer-early-data-suggest/followhttps://immuno-oncologynews.com/2020/12/21/io102-io103-cancer-vaccines-get-fda-breakthrough-status-in-advanced-melanoma-combo-therapy/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapyfollowhttps://immuno-oncologynews.com/2020/12/21/io102-io103-cancer-vaccines-get-fda-breakthrough-status-in-advanced-melanoma-combo-therapy/December 21, 2020December 21, 2020followhttps://immuno-oncologynews.com/2020/12/21/io102-io103-cancer-vaccines-get-fda-breakthrough-status-in-advanced-melanoma-combo-therapy/followhttps://immuno-oncologynews.com/2020/12/21/io102-io103-cancer-vaccines-get-fda-breakthrough-status-in-advanced-melanoma-combo-therapy/The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to ...followhttps://immuno-oncologynews.com/2020/12/21/io102-io103-cancer-vaccines-get-fda-breakthrough-status-in-advanced-melanoma-combo-therapy/followhttps://immuno-oncologynews.com/2020/12/18/immunocore-tebentafusp-seen-prolong-life-advanced-eye-cancer-patients-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tebentafusp Prolongs Life for Those With Advanced Eye Cancer, Trial Findsfollowhttps://immuno-oncologynews.com/2020/12/18/immunocore-tebentafusp-seen-prolong-life-advanced-eye-cancer-patients-trial-data-show/December 18, 2020December 18, 2020followhttps://immuno-oncologynews.com/2020/12/18/immunocore-tebentafusp-seen-prolong-life-advanced-eye-cancer-patients-trial-data-show/followhttps://immuno-oncologynews.com/2020/12/18/immunocore-tebentafusp-seen-prolong-life-advanced-eye-cancer-patients-trial-data-show/Immunocore’s investigational immunotherapy tebentafusp (IMCgp100) is superior to investigator’s choice at prolonging the lives of ...followhttps://immuno-oncologynews.com/2020/12/18/immunocore-tebentafusp-seen-prolong-life-advanced-eye-cancer-patients-trial-data-show/followhttps://immuno-oncologynews.com/2020/12/16/ema-committee-recommends-eu-approval-bavencio-as-initial-maintenance-treatment-for-bladder-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/EU Approval Urged for Bavencio as Maintenance Therapy for Bladder Cancerfollowhttps://immuno-oncologynews.com/2020/12/16/ema-committee-recommends-eu-approval-bavencio-as-initial-maintenance-treatment-for-bladder-cancer/December 16, 2020December 16, 2020followhttps://immuno-oncologynews.com/2020/12/16/ema-committee-recommends-eu-approval-bavencio-as-initial-maintenance-treatment-for-bladder-cancer/followhttps://immuno-oncologynews.com/2020/12/16/ema-committee-recommends-eu-approval-bavencio-as-initial-maintenance-treatment-for-bladder-cancer/A European Medicines Agency (EMA) committee has adopted a positive opinion on Bavencio (avelumab), recommending ...followhttps://immuno-oncologynews.com/2020/12/16/ema-committee-recommends-eu-approval-bavencio-as-initial-maintenance-treatment-for-bladder-cancer/followhttps://immuno-oncologynews.com/2020/12/14/keytruda-approval-recommended-in-eu-as-first-line-therapy-for-certain-advanced-colorectal-cancers/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda Approval Recommended in EU as First-line Therapy for Certain Colorectal Cancersfollowhttps://immuno-oncologynews.com/2020/12/14/keytruda-approval-recommended-in-eu-as-first-line-therapy-for-certain-advanced-colorectal-cancers/December 14, 2020December 14, 2020followhttps://immuno-oncologynews.com/2020/12/14/keytruda-approval-recommended-in-eu-as-first-line-therapy-for-certain-advanced-colorectal-cancers/followhttps://immuno-oncologynews.com/2020/12/14/keytruda-approval-recommended-in-eu-as-first-line-therapy-for-certain-advanced-colorectal-cancers/Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) as a first-line ...followhttps://immuno-oncologynews.com/2020/12/14/keytruda-approval-recommended-in-eu-as-first-line-therapy-for-certain-advanced-colorectal-cancers/followhttps://immuno-oncologynews.com/2020/12/11/yescarta-shows-promise-in-advanced-non-hodgkin-lymphomas-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Yescarta Shows Promise in Advanced Non-Hodgkin Lymphomas, Trial Data Showfollowhttps://immuno-oncologynews.com/2020/12/11/yescarta-shows-promise-in-advanced-non-hodgkin-lymphomas-trial-data-show/December 11, 2020December 11, 2020followhttps://immuno-oncologynews.com/2020/12/11/yescarta-shows-promise-in-advanced-non-hodgkin-lymphomas-trial-data-show/followhttps://immuno-oncologynews.com/2020/12/11/yescarta-shows-promise-in-advanced-non-hodgkin-lymphomas-trial-data-show/Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses ...followhttps://immuno-oncologynews.com/2020/12/11/yescarta-shows-promise-in-advanced-non-hodgkin-lymphomas-trial-data-show/followhttps://immuno-oncologynews.com/2020/12/09/tislelizumab-safely-prolongs-survival-advanced-lung-cancer-patients-interim-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Tislelizumab Safely Prolongs Survival in Advanced Lung Cancer Patients, Interim Data Showfollowhttps://immuno-oncologynews.com/2020/12/09/tislelizumab-safely-prolongs-survival-advanced-lung-cancer-patients-interim-data-show/December 9, 2020December 9, 2020followhttps://immuno-oncologynews.com/2020/12/09/tislelizumab-safely-prolongs-survival-advanced-lung-cancer-patients-interim-data-show/followhttps://immuno-oncologynews.com/2020/12/09/tislelizumab-safely-prolongs-survival-advanced-lung-cancer-patients-interim-data-show/When given as a second- or third-line therapy, BeiGene’s tislelizumab is superior to docetaxel at ...followhttps://immuno-oncologynews.com/2020/12/09/tislelizumab-safely-prolongs-survival-advanced-lung-cancer-patients-interim-data-show/followhttps://immuno-oncologynews.com/2020/12/07/fda-approves-less-frequent-regimen-imfinzi-nsclc-bladder-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancerfollowhttps://immuno-oncologynews.com/2020/12/07/fda-approves-less-frequent-regimen-imfinzi-nsclc-bladder-cancer/December 7, 2020December 7, 2020followhttps://immuno-oncologynews.com/2020/12/07/fda-approves-less-frequent-regimen-imfinzi-nsclc-bladder-cancer/followhttps://immuno-oncologynews.com/2020/12/07/fda-approves-less-frequent-regimen-imfinzi-nsclc-bladder-cancer/The U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for Imfinzi (durvalumab) for ...followhttps://immuno-oncologynews.com/2020/12/07/fda-approves-less-frequent-regimen-imfinzi-nsclc-bladder-cancer/followhttps://immuno-oncologynews.com/2020/12/04/keytruda-lenvima-combo-in-advanced-kidney-cancer-better-than-sutent-in-improving-survival-outcomes-top-line-trial-data-show/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Keytruda-Lenvima Combo in Kidney Cancer Better Than Sutent in Improving Survivalfollowhttps://immuno-oncologynews.com/2020/12/04/keytruda-lenvima-combo-in-advanced-kidney-cancer-better-than-sutent-in-improving-survival-outcomes-top-line-trial-data-show/December 4, 2020December 4, 2020followhttps://immuno-oncologynews.com/2020/12/04/keytruda-lenvima-combo-in-advanced-kidney-cancer-better-than-sutent-in-improving-survival-outcomes-top-line-trial-data-show/followhttps://immuno-oncologynews.com/2020/12/04/keytruda-lenvima-combo-in-advanced-kidney-cancer-better-than-sutent-in-improving-survival-outcomes-top-line-trial-data-show/A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) in ...followhttps://immuno-oncologynews.com/2020/12/04/keytruda-lenvima-combo-in-advanced-kidney-cancer-better-than-sutent-in-improving-survival-outcomes-top-line-trial-data-show/followhttps://immuno-oncologynews.com/2020/11/30/opdivo-approved-europe-second-line-therapy-advanced-esophageal-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancerfollowhttps://immuno-oncologynews.com/2020/11/30/opdivo-approved-europe-second-line-therapy-advanced-esophageal-cancer/November 30, 2020November 30, 2020followhttps://immuno-oncologynews.com/2020/11/30/opdivo-approved-europe-second-line-therapy-advanced-esophageal-cancer/followhttps://immuno-oncologynews.com/2020/11/30/opdivo-approved-europe-second-line-therapy-advanced-esophageal-cancer/The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced ...followhttps://immuno-oncologynews.com/2020/11/30/opdivo-approved-europe-second-line-therapy-advanced-esophageal-cancer/followhttps://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancerfollowhttps://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/November 25, 2020November 25, 2020followhttps://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/followhttps://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/Merck has decided to suspend its Phase 3 trial that was assessing a combination of Yervoy ...followhttps://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/followhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in USfollowhttps://immuno-oncologynews.com/2021/03/05/keytruda-use-us-stopped-advanced-small-cell-lung-cancer/followhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patientsfollowhttps://immuno-oncologynews.com/2021/03/03/ilixadencel-sutent-combo-meaningful-survival-newly-diagnosed-metastatic-kidney-cancer-phase-2-trial-shows/followhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/Imfinzi No Longer Available in US for Advanced Bladder Cancerfollowhttps://immuno-oncologynews.com/2021/03/01/imfinzi-no-longer-available-us-advanced-bladder-cancer-patients-astrazeneca-announces-product-withdrawl/FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancerfollowhttps://immuno-oncologynews.com/2020/07/02/advanced-bladder-cancer-maintenance-therapy-bavencio-approved-by-fda/followhttps://immuno-oncologynews.com/2020/07/02/advanced-bladder-cancer-maintenance-therapy-bavencio-approved-by-fda/FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancersfollowhttps://immuno-oncologynews.com/2020/07/01/fda-approves-keytruda-first-line-therapy-certain-advanced-colorectal-cancers/followhttps://immuno-oncologynews.com/2020/07/01/fda-approves-keytruda-first-line-therapy-certain-advanced-colorectal-cancers/FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trialsfollowhttps://immuno-oncologynews.com/2020/06/30/new-fda-program-project-patient-voice-will-share-patient-reported-outcomes-from-cancer-clinical-trials/followhttps://immuno-oncologynews.com/2020/06/30/new-fda-program-project-patient-voice-will-share-patient-reported-outcomes-from-cancer-clinical-trials/Visit Immuno-Oncology News"s profile on Pinterest.followhttps://www.pinterest.com/immunooncologyn/May 9, 2018May 9, 2018followhttps://immuno-oncologynews.com/2018/05/09/researchers-may-now-predict-which-cll-patients-respond-kymriah/Researchers May Now Predict Which CLL Patients Will Respond to Kymriah CAR T-Cell Therapy, Study Saysfollowhttps://immuno-oncologynews.com/2018/05/09/researchers-may-now-predict-which-cll-patients-respond-kymriah/Newsfollowhttps://immuno-oncologynews.com/category/news-posts/Read morefollowhttps://immuno-oncologynews.com/2018/05/09/researchers-may-now-predict-which-cll-patients-respond-kymriah/followhttps://bionewsservices.comBioNews Services, LLCfollowhttps://bionews.com[email protected]follow/cdn-cgi/l/email-protection#99f0f7fff6d9fbf0f6f7fceeeab7faf6f4+1-800-936-1363followtel:+18009361363Publishing Teamfollowhttps://bionews.com/publishing-team/Leadershipfollowhttps://bionewsservices.com/team/Our Valuesfollowhttps://bionews.com/our-values/Corrections Policyfollowhttps://bionews.com/corrections-policy/Contact Usfollowhttps://bionews.com/contact-us/Privacy Policyfollowhttps://immuno-oncologynews.com/privacy-policy/Terms of Servicefollowhttps://immuno-oncologynews.com/terms-service/Disable Notificationsfollowhttps://bionewsservices.com/disable-notifications/follow#
- Social signals
- Title: 48 characters.
- Description: 130 characters.
- Domain Authority
- Monthly pages viewed: 11111
- Estimated worth: 5087 dollars
We have developed a useful service for retrieve WhoIs information. "Whois" is a term that begins from the early days of the Internet, based on Unix operating system and university networks. On the Unix console, the command "whois" tries to determine the identity of the domain's registrant.
It is a means for Internet users to query various types of information such as IP addresses, user data and also domain data.
✦ SEO Report
Title / Meta tags
Immuno-Oncology News Home - Immuno-Oncology News
-->Immuno-Oncology News Home - Immuno-Oncology News Skip to contentHomeCategoriesImmune Checkpoint InhibitorsT cellsPD-1MelanomaB
Image Analysis
A right example for an HTML image tag:
<img src="prettyimage.jpg" alt="image description" title="image tooltip"/>
For SEO performance, you must write an alternative text. The alternative text must describe the image's content. Also, the alt tag is used for blind people. Their browsers tell them all about the description of the image.
Heading
Content Analysis
Code Analysis
We have found hyphens (-) or underscores (_) in your URL. Google and expert domainers do not recommend buying domains with hyphens or underscores.
When a visitor came to your website you can not fail. The user wants your page to load in a second. You know that it is difficult sometimes to display content in the first second but if the user has to wait too much time you can lose that user. If your page is too slow, you will lose a lot of web traffic. Your project URL load time is ms, it is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.immuno-oncologynews.com is as follows:
A huge portion of visitors to your website are usually in rush and nobody is fond of waiting too much before your website loads its content. If your website is slow, you will lose a lot of visitors. Your homepage load time is ms is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.immuno-oncologynews.com is as follows:
Speed:
Page Load Time: ms
header-ad-space, hfeed site, site-header static-menu header-layout1 show-search, inner-header, site-branding, site-title logo-title, social-area custom-color header-social-icons, menu-toggle, fa fa-bars, main-navigation, inner-nav, skip-link screen-reader-text, menu-top-container, menu, menu-item menu-item-type-custom menu-item-object-custom current-menu-item current_page_item menu-item-home menu-item-23, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3461, sub-menu, menu-item menu-item-type-post_type menu-item-object-page menu-item-16274, menu-item menu-item-type-taxonomy menu-item-object-post_tag menu-item-3463, menu-item menu-item-type-taxonomy menu-item-object-post_tag menu-item-3464, menu-item menu-item-type-taxonomy menu-item-object-post_tag menu-item-3465, menu-item menu-item-type-taxonomy menu-item-object-post_tag menu-item-3466, menu-item menu-item-type-taxonomy menu-item-object-post_tag menu-item-3467, menu-item menu-item-type-taxonomy menu-item-object-post_tag menu-item-3468, menu-item menu-item-type-post_type menu-item-object-page menu-item-3256, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14430, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-12779, menu-item menu-item-type-post_type menu-item-object-page menu-item-12919, menu-item menu-item-type-post_type menu-item-object-page menu-item-12920, menu-item menu-item-type-post_type menu-item-object-page menu-item-12921, menu-item menu-item-type-post_type menu-item-object-page menu-item-12922, menu-item menu-item-type-post_type menu-item-object-page menu-item-16273, menu-item menu-item-type-post_type menu-item-object-page menu-item-16377, menu-item menu-item-type-post_type menu-item-object-page menu-item-12924, menu-item menu-item-type-post_type menu-item-object-page menu-item-16376, menu-item menu-item-type-post_type menu-item-object-page menu-item-12858, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-12740, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14431, menu-item menu-item-type-post_type menu-item-object-page menu-item-12780, menu-item menu-item-type-post_type menu-item-object-page menu-item-12781, menu-item menu-item-type-post_type menu-item-object-page menu-item-12782, menu-item menu-item-type-post_type menu-item-object-page menu-item-14293, menu-item menu-item-type-post_type menu-item-object-page menu-item-12783, menu-item menu-item-type-post_type menu-item-object-page menu-item-12784, menu-item menu-item-type-post_type menu-item-object-page menu-item-12785, menu-item menu-item-type-post_type menu-item-object-page menu-item-12786, menu-item menu-item-type-post_type menu-item-object-page menu-item-12787, menu-item menu-item-type-post_type menu-item-object-page menu-item-12788, menu-item menu-item-type-post_type menu-item-object-page menu-item-12789, menu-item menu-item-type-post_type menu-item-object-page menu-item-12790, menu-item menu-item-type-post_type menu-item-object-page menu-item-12791, menu-item menu-item-type-post_type menu-item-object-page menu-item-12792, menu-item menu-item-type-post_type menu-item-object-page menu-item-12793, menu-item menu-item-type-post_type menu-item-object-page menu-item-12794, menu-item menu-item-type-post_type menu-item-object-page menu-item-12795, menu-item menu-item-type-post_type menu-item-object-page menu-item-12796, menu-item menu-item-type-post_type menu-item-object-page menu-item-12797, menu-item menu-item-type-post_type menu-item-object-page menu-item-12798, menu-item menu-item-type-post_type menu-item-object-page menu-item-12799, menu-item menu-item-type-post_type menu-item-object-page menu-item-12800, menu-item menu-item-type-post_type menu-item-object-page menu-item-12801, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14432, menu-item menu-item-type-post_type menu-item-object-page menu-item-12802, menu-item menu-item-type-post_type menu-item-object-page menu-item-14294, menu-item menu-item-type-post_type menu-item-object-page menu-item-12803, menu-item menu-item-type-post_type menu-item-object-page menu-item-14296, menu-item menu-item-type-post_type menu-item-object-page menu-item-14295, menu-item menu-item-type-post_type menu-item-object-page menu-item-12804, menu-item menu-item-type-post_type menu-item-object-page menu-item-12805, menu-item menu-item-type-post_type menu-item-object-page menu-item-12806, menu-item menu-item-type-post_type menu-item-object-page menu-item-12807, menu-item menu-item-type-post_type menu-item-object-page menu-item-12808, menu-item menu-item-type-post_type menu-item-object-page menu-item-12809, menu-item menu-item-type-post_type menu-item-object-page menu-item-12810, menu-item menu-item-type-post_type menu-item-object-page menu-item-12811, menu-item menu-item-type-post_type menu-item-object-page menu-item-12812, menu-item menu-item-type-post_type menu-item-object-page menu-item-14297, menu-item menu-item-type-post_type menu-item-object-page menu-item-12813, menu-item menu-item-type-post_type menu-item-object-page menu-item-14298, menu-item menu-item-type-post_type menu-item-object-page menu-item-12814, menu-item menu-item-type-post_type menu-item-object-page menu-item-17712, menu-item menu-item-type-post_type menu-item-object-page menu-item-12815, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14433, menu-item menu-item-type-post_type menu-item-object-page menu-item-12816, menu-item menu-item-type-post_type menu-item-object-page menu-item-12817, menu-item menu-item-type-post_type menu-item-object-page menu-item-12818, menu-item menu-item-type-post_type menu-item-object-page menu-item-12819, menu-item menu-item-type-post_type menu-item-object-page menu-item-12820, menu-item menu-item-type-post_type menu-item-object-page menu-item-14299, menu-item menu-item-type-post_type menu-item-object-page menu-item-12821, menu-item menu-item-type-post_type menu-item-object-page menu-item-12822, menu-item menu-item-type-post_type menu-item-object-page menu-item-12823, menu-item menu-item-type-post_type menu-item-object-page menu-item-12824, menu-item menu-item-type-post_type menu-item-object-page menu-item-12825, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14434, menu-item menu-item-type-post_type menu-item-object-page menu-item-12826, menu-item menu-item-type-post_type menu-item-object-page menu-item-12827, menu-item menu-item-type-post_type menu-item-object-page menu-item-12828, menu-item menu-item-type-post_type menu-item-object-page menu-item-12829, menu-item menu-item-type-post_type menu-item-object-page menu-item-12830, menu-item menu-item-type-post_type menu-item-object-page menu-item-12831, menu-item menu-item-type-post_type menu-item-object-page menu-item-12832, menu-item menu-item-type-post_type menu-item-object-page menu-item-12833, menu-item menu-item-type-post_type menu-item-object-page menu-item-12834, menu-item menu-item-type-post_type menu-item-object-page menu-item-12835, menu-item menu-item-type-post_type menu-item-object-page menu-item-12836, menu-item menu-item-type-post_type menu-item-object-page menu-item-12837, menu-item menu-item-type-post_type menu-item-object-page menu-item-12838, menu-item menu-item-type-post_type menu-item-object-page menu-item-12839, menu-item menu-item-type-post_type menu-item-object-page menu-item-12840, menu-item menu-item-type-post_type menu-item-object-page menu-item-12841, menu-item menu-item-type-post_type menu-item-object-page menu-item-12842, menu-item menu-item-type-post_type menu-item-object-page menu-item-12844, menu-item menu-item-type-post_type menu-item-object-page menu-item-12845, menu-item menu-item-type-post_type menu-item-object-page menu-item-12846, menu-item menu-item-type-post_type menu-item-object-page menu-item-12847, menu-item menu-item-type-post_type menu-item-object-page menu-item-12848, menu-item menu-item-type-post_type menu-item-object-page menu-item-12849, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14435, menu-item menu-item-type-post_type menu-item-object-page menu-item-12850, menu-item menu-item-type-post_type menu-item-object-page menu-item-12851, menu-item menu-item-type-post_type menu-item-object-page menu-item-12852, menu-item menu-item-type-post_type menu-item-object-page menu-item-12853, menu-item menu-item-type-post_type menu-item-object-page menu-item-12854, menu-item menu-item-type-post_type menu-item-object-page menu-item-12855, menu-item menu-item-type-post_type menu-item-object-page menu-item-12856, menu-item menu-item-type-post_type menu-item-object-page menu-item-12857, menu-item menu-item-type-post_type menu-item-object-page menu-item-12859, menu-item menu-item-type-post_type menu-item-object-page menu-item-12860, menu-item menu-item-type-post_type menu-item-object-page menu-item-12861, menu-item menu-item-type-post_type menu-item-object-page menu-item-12862, menu-item menu-item-type-post_type menu-item-object-page menu-item-12863, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14436, menu-item menu-item-type-post_type menu-item-object-page menu-item-12864, menu-item menu-item-type-post_type menu-item-object-page menu-item-12865, menu-item menu-item-type-post_type menu-item-object-page menu-item-12867, menu-item menu-item-type-post_type menu-item-object-page menu-item-12868, menu-item menu-item-type-post_type menu-item-object-page menu-item-12869, menu-item menu-item-type-post_type menu-item-object-page menu-item-12870, menu-item menu-item-type-post_type menu-item-object-page menu-item-12871, menu-item menu-item-type-post_type menu-item-object-page menu-item-12873, menu-item menu-item-type-post_type menu-item-object-page menu-item-12874, menu-item menu-item-type-post_type menu-item-object-page menu-item-12875, menu-item menu-item-type-post_type menu-item-object-page menu-item-12876, menu-item menu-item-type-post_type menu-item-object-page menu-item-12877, menu-item menu-item-type-post_type menu-item-object-page menu-item-12878, menu-item menu-item-type-post_type menu-item-object-page menu-item-12879, menu-item menu-item-type-post_type menu-item-object-page menu-item-12880, menu-item menu-item-type-post_type menu-item-object-page menu-item-12881, menu-item menu-item-type-post_type menu-item-object-page menu-item-12882, menu-item menu-item-type-post_type menu-item-object-page menu-item-12883, menu-item menu-item-type-post_type menu-item-object-page menu-item-12884, menu-item menu-item-type-post_type menu-item-object-page menu-item-14300, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14437, menu-item menu-item-type-post_type menu-item-object-page menu-item-12885, menu-item menu-item-type-post_type menu-item-object-page menu-item-12886, menu-item menu-item-type-post_type menu-item-object-page menu-item-12887, menu-item menu-item-type-post_type menu-item-object-page menu-item-12888, menu-item menu-item-type-post_type menu-item-object-page menu-item-12889, menu-item menu-item-type-post_type menu-item-object-page menu-item-12890, menu-item menu-item-type-post_type menu-item-object-page menu-item-12891, menu-item menu-item-type-post_type menu-item-object-page menu-item-12892, menu-item menu-item-type-post_type menu-item-object-page menu-item-14302, menu-item menu-item-type-post_type menu-item-object-page menu-item-12893, menu-item menu-item-type-post_type menu-item-object-page menu-item-14303, menu-item menu-item-type-post_type menu-item-object-page menu-item-12894, menu-item menu-item-type-post_type menu-item-object-page menu-item-12895, menu-item menu-item-type-post_type menu-item-object-page menu-item-12896, menu-item menu-item-type-post_type menu-item-object-page menu-item-12897, menu-item menu-item-type-post_type menu-item-object-page menu-item-12898, menu-item menu-item-type-post_type menu-item-object-page menu-item-12899, menu-item menu-item-type-post_type menu-item-object-page menu-item-12900, menu-item menu-item-type-post_type menu-item-object-page menu-item-12901, menu-item menu-item-type-post_type menu-item-object-page menu-item-12902, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-14438, menu-item menu-item-type-post_type menu-item-object-page menu-item-14304, menu-item menu-item-type-post_type menu-item-object-page menu-item-12903, menu-item menu-item-type-post_type menu-item-object-page menu-item-12904, menu-item menu-item-type-post_type menu-item-object-page menu-item-12905, menu-item menu-item-type-post_type menu-item-object-page menu-item-12906, menu-item menu-item-type-post_type menu-item-object-page menu-item-12907, menu-item menu-item-type-post_type menu-item-object-page menu-item-12908, menu-item menu-item-type-post_type menu-item-object-page menu-item-12909, menu-item menu-item-type-post_type menu-item-object-page menu-item-12910, menu-item menu-item-type-post_type menu-item-object-page menu-item-12911, menu-item menu-item-type-post_type menu-item-object-page menu-item-12912, menu-item menu-item-type-post_type menu-item-object-page menu-item-12913, menu-item menu-item-type-post_type menu-item-object-page menu-item-12914, menu-item menu-item-type-post_type menu-item-object-page menu-item-14305, menu-item menu-item-type-post_type menu-item-object-page menu-item-14306, menu-item menu-item-type-post_type menu-item-object-page menu-item-12915, menu-item menu-item-type-post_type menu-item-object-page menu-item-12916, menu-item menu-item-type-post_type menu-item-object-page menu-item-12917, menu-item menu-item-type-post_type menu-item-object-page menu-item-12918, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-36503, menu-item menu-item-type-custom menu-item-object-custom menu-item-36488, header-search, search-form, screen-reader-text, search-field, search-submit, search-handler, site-content, modular-wrapper, modular-modules header-hide, post-14926 page type-page status-publish hentry, quadro-mod type-flashnews , inner-mod, mod-header, mod-title, flashnews slides clear, flashnews-item, flashnews-content, cat-links, entry-title, quadro-mod type-display with-margins , mod-editor-content, uab-frontend-wrapper-outer, uab-frontend-inner-layer uab-frontend-wrapper-author-3 , display-wrapper display-layout2, clear, display-item display-item1 post-36951 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-fda tag-keynote-604 tag-keytruda tag-merck tag-pembrolizumab tag-small-cell-lung-cancer, display-back-img, post-icon, display-content altered3, posted-on, entry-date published, updated, entry-summary, readmore-link, read-more, display-item display-item2 post-36920 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-ilixadencel tag-immunicum tag-mereca-phase-2-trial tag-sunitinib tag-sutent, display-item display-item3 post-36914 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-astrazeneca tag-bladder-cancer tag-conditional-approval tag-danube-phase-3-trial tag-durvalumab tag-failure tag-fda tag-imfinzi tag-voluntary-withdrawal, display-item display-item4 post-36817 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-affimed tag-afm24 tag-cell-engager tag-clinical-trial tag-collaboration-agreement tag-egfr tag-roche, display-item display-item5 post-36908 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-breakthrough-therapy-designation tag-fda tag-imcgp100 tag-immunocore tag-immunotherapy tag-tebentafusp tag-u-s-food-and-drug-administration, quadro-mod type-magazine magazine-layout4 mag-columns-three , magazine-item magazine-item1 post-36880 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-advanced-renal-cell-carcinoma tag-disease-progression tag-eisai tag-keynote-581-clear-study-307-phase-3-trial tag-keytruda-lenvima-combo tag-lenvima-afinitor-combo tag-merck tag-survival tag-sutent, entry-thumbnail, magazine-content altered3, entry-summary altered3, magazine-item magazine-item2 post-36843 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-adjuvant-therapy tag-bristol-myers-squibb tag-cancer-recurrence tag-checkmate-274-phase-3-trial tag-muscle-invasive-urothelial-carcinoma tag-nivolumab tag-opdivo, magazine-item magazine-item3 post-36491 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-ccr4 tag-charged-tumors tag-flx475 tag-keytruda tag-pembrolizumab tag-phase-12-trial tag-preliminary-data tag-rapt-therapeutics tag-recruiting tag-regulatory-t-cells tag-tregs, magazine-item magazine-item4 post-36690 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-biond-biologics tag-bnd-22 tag-cancer-immunotherapy tag-immune-checkpoint-inhibitors tag-immunotherapy tag-sanofi, magazine-item magazine-item5 post-36854 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-advanced-basal-cell-carcinoma tag-fda-approved tag-libtayo tag-regeneron-pharmaceuticals tag-sanofi, magazine-item magazine-item6 post-36834 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-b-cell tag-breyanzi tag-bristol-myers-squibb tag-car-t-cell tag-cd19 tag-fda tag-fda-approval tag-jcar017 tag-liso-cel tag-lisocabtagene-maraleucel, quadro-mod type-leadbox layout-layout10 , inner-mod clear, leadbox-wrapper, leadbox-content, leadbox-text-wrapper, leadbox-title, leadbox-text, leadbox-form-wrapper, leadbox-form two-inputs clear, at-leadbox-name, at-leadbox-email, at-leadbox-submit qbtn, leadbox-loader, fa fa-spinner fa-spin, leadbox-submit-msg, quadro-mod type-wrapper sidebar-right clear , inner-mod-wrapper, modules-wrapper, quadro-mod type-magazine magazine-layout2 mag-columns-two , magazine-item magazine-item1 post-36811 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-bristol-myers-squibb tag-keynote-598-phase-3-trial tag-keytruda tag-merck tag-non-small-cell-lung-cancer tag-nsclc tag-pembrolizumab tag-yervoy, magazine-item magazine-item2 post-36693 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-cancer-immunotherapy tag-car-nk-cell tag-cytovia-therapeutics tag-glypican-3 tag-gpc3-car-nk-cell-therapy tag-hepatocellular-carcinoma tag-national-cancer-institute tag-natural-killer tag-off-the-shelf, magazine-item magazine-item3 post-36798 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-chmp tag-classical-hodgkins-lymphoma tag-eu tag-keynote-087-phase-2-trial tag-keynote-204-phase-3-trial tag-keytruda tag-merck, magazine-item magazine-item4 post-36545 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-istari-oncology tag-keytruda tag-luminos-101 tag-merck tag-pembrolizumab tag-pvsripo tag-recurrent-glioblastoma-multiforme tag-rgbm, magazine-item magazine-item5 post-36767 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-advanced-colorectal-cancer tag-approval tag-deficient-mismatch-repair tag-dmmr tag-europe tag-keynote-177-phase-3-trial tag-keytruda tag-merck tag-microsatellite-instability-high tag-msi-h tag-pembrolizumab, magazine-item magazine-item6 post-36765 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-approval tag-avelumab tag-bavencio tag-bladder-cancer tag-emd-serono tag-european-commission tag-first-line-maintenance-treatment tag-merck tag-pfizer, quadro-mod type-magazine magazine-layout1 mag-columns-two , magazine-item magazine-item1 post-36748 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-fda tag-incyte tag-priority-review tag-retifanlimab tag-squamous-cell-carcinoma-of-the-anal-canal, magazine-item magazine-item2 post-36738 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-bristol-myers-squibb tag-checkmate-577-phase-3-trial tag-checkmate-649-phase-3-trial tag-esophageal-cancer tag-fda tag-gastric-cancer tag-nivolumab tag-opdivo tag-priority-review, magazine-item magazine-item3 post-36686 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-atezolizumab tag-avastin tag-bevacizumab tag-genentech tag-hcc tag-hepatocellular-carcinoma tag-imbrave150-phase-3-trial tag-nexavar tag-roche tag-sorafenib tag-tecentriq, magazine-item magazine-item4 post-36706 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-advanced-nsclc tag-approval tag-astrazeneca tag-caspian-phase-3-trial tag-durvalumab tag-european-union tag-imfinzi tag-non-small-cell-lung-cancer tag-pacific-phase-3-trial tag-uk, quadro-mod type-magazine magazine-layout3 mag-columns-two , magazine-item magazine-item1 post-36506 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-adaptimmune-therapeutics tag-adp-a2m4 tag-clinical-trial tag-spearhead-1-phase-2-trial tag-synovial-sarcoma tag-t-cell, magazine-item magazine-item2 post-36489 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-aivita-biomedical tag-av-gbm-1 tag-cancer-vaccine tag-cancer-specific-proteins tag-dendritic-cells tag-glioblastoma tag-melanoma tag-ovarian-cancer tag-overall-survival tag-progression-free-survival, magazine-item magazine-item3 post-36451 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-cavrotolimod tag-exicure tag-keytruda tag-libtayo tag-pd-1-blockade tag-phase-1b-2-clinical-trial, magazine-item magazine-item1 post-36658 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-atezolizumab tag-breakthrough-therapy-designation tag-cityscape-phase-2-trial tag-fda tag-genentech tag-metastatic-non-small-cell-lung-cancer tag-nsclc tag-tecentriq tag-tiragolumab, magazine-item magazine-item2 post-36516 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-anti-tumor-immune-responses tag-cancer-vaccine tag-glioblastoma tag-hard-to-treat-patients tag-immune-checkpoint-inhibitor tag-ino-5401 tag-ino-9012 tag-inovio-pharmaceuticals tag-libtayo tag-mgmt-promoter-methylation-status tag-regeneron-pharmaceuticals, magazine-item magazine-item3 post-36620 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-breakthrough-therapy-designation tag-cancer-vaccine tag-io-biotech tag-io102 tag-io103 tag-melanoma tag-mm1636 tag-nivolumab tag-opdivo, magazine-item magazine-item4 post-36526 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-bispecific-antibody tag-imcgp100 tag-imcgp100-102-phase-2-study tag-imcgp100-202-phase-3-trial tag-immunocore tag-metastatic-uveal-melanoma tag-tebentafusp, magazine-item magazine-item5 post-36606 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-avelumab tag-bavencio tag-chmp tag-ema tag-emd-serono tag-immune-checkpoint-inhibitor tag-javelin-bladder-100-phase-3-trial tag-merck-kgaa tag-pd-l1 tag-pfizer tag-urothelial-carcinoma, magazine-item magazine-item6 post-36587 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-chmp tag-colorectal-cancer tag-deficient-mismatch-repair tag-keynote-177-phase-3-trial tag-keytruda tag-microsatellite-instability-high tag-msd-merck tag-pembrolizumab, magazine-item magazine-item7 post-36566 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-follicular-lymphoma tag-gilead-sciences tag-indolent-nhl tag-kite-pharma tag-marginal-zone-lymphoma tag-priority-review tag-relapsed-or-refractory-indolent-non-hodgkins-lymphoma tag-yescarta tag-zuma-5-phase-2-trial, magazine-item magazine-item8 post-36501 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-beigene tag-docetaxel tag-immune-checkpoint-inhibitor tag-nsclc tag-rationale-303-phase-3-trial tag-tislelizumab, magazine-item magazine-item9 post-36518 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-approval tag-astrazeneca tag-bladder-cancer tag-durvalumab tag-imfinzi tag-immune-checkpoint-inhibitor tag-non-small-cell-lung-cancer tag-once-monthly tag-u-s-food-and-drug-administration, magazine-item magazine-item10 post-36470 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-advanced-renal-cell-carcinoma tag-eisai tag-keynote-581-clear-study-307-phase-3-trial tag-keytruda tag-keytruda-lenvima-combo tag-lenvima tag-lenvima-afinitor-combo tag-merck tag-novartis, magazine-item magazine-item11 post-36533 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-attraction-3-phase-3-trial tag-bristol-myers-squibb tag-escc tag-esophageal-squamous-cell-carcinoma tag-nivolumab tag-opdivo, magazine-item magazine-item12 post-36468 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-ipilimumab tag-keynote-598-phase-3-trial tag-keytruda tag-merck tag-non-small-cell-lung-cancer tag-nsclc tag-pembrolizumab tag-yervoy, widget-area, widget widget_search, widget widget_text, textwidget, widget quadro-recents-widget, widget-title, quadro-rpost clear, quadro-rpost-thumb-link, attachment-thumbnail size-thumbnail wp-post-image, quadro-rpost-data, meta, widget quadro-featured-widget, quadro-feat-post clear, quadro-feat-post-data, quadro-feat-post-thumb-link, attachment-medium size-medium wp-post-image, quadro-mod type-featured , featured-item clear feat-type1 post-14321 post type-post status-publish format-standard has-post-thumbnail hentry category-news-posts tag-biomarkers tag-car-t-cell-therapy tag-immuno-oncology tag-kymriah tag-novartis tag-tisagenlecleucel tag-upenn-school-of-medicine, feat-post-img, feat-item-content, feat-item-title, feat-item-text, site-footer, inner-footer clear, widg-layout2, alignleft size-full wp-image-12811, __cf_email__, widget widget_nav_menu, menu-footer-menu-container, menu-item menu-item-type-custom menu-item-object-custom menu-item-35886, menu-item menu-item-type-custom menu-item-object-custom menu-item-16155, menu-item menu-item-type-custom menu-item-object-custom menu-item-16156, menu-item menu-item-type-custom menu-item-object-custom menu-item-35887, menu-item menu-item-type-custom menu-item-object-custom menu-item-36303, menu-item menu-item-type-post_type menu-item-object-page menu-item-400, menu-item menu-item-type-post_type menu-item-object-page menu-item-401, menu-item menu-item-type-custom menu-item-object-custom menu-item-16157, bottom-footer clear, site-info, social-area brand-color footer-social-icons, back-to-top,
How much money does immuno-oncologynews.com earn?
The domain immuno-oncologynews.com has a revenue of $38.8885 monthly. We have calculated this earning based on the daily traffic of this domain.
Has immuno-oncologynews.com Google Analytics code?
The domain immuno-oncologynews.com has the Google Analytics code inside its HTML.
Has immuno-oncologynews.com Google Adsense code?
The Analytics id for immuno-oncologynews.com is 37672582
.
The domain immuno-oncologynews.com has not the Google Adsense code inside its HTML.
What IP immuno-oncologynews.com has?
The domain immuno-oncologynews.com has IP 172.67.135.121.
Which charset immuno-oncologynews.com has?
An IP address is a string of numbers used to make devices accessible for communication.
The domain immuno-oncologynews.com has the charset UTF-8.
How many internal links immuno-oncologynews.com has?
To display an HTML page correctly, a web browser must know which character set to use.
The charset change for every language set of characters like English, Chinese or Russian.
The domain immuno-oncologynews.com has 0 links.
How many words immuno-oncologynews.com has?
The links are an important part of the web.
The links help us to navigate between pages.
The domain immuno-oncologynews.com has 2648 words.
The number of words is a crucial metric of the website.
The websites need a large quantity of text to explain the content of the site
Last visited